quinupristin-dalfopristin (Synercid)

09/01/1999 - "The combined results from a Phase III non-comparative study and an emergency-use study of quinupristin/dalfopristin for the treatment of VREF infection produced a clinical response rate (cure or improvement) in 142 (73.6%) of 193 clinically evaluable patients. "
03/01/2000 - "Quinupristin/dalfopristin was well-tolerated and generally effective in children with infections caused by VREF. "
01/01/1995 - "Clinical evidence to date indicates that quinupristin/dalfopristin may be effective for the treatment of multidrug-resistant infections, especially those due to vancomycin-resistant enterococci and methicillin-resistant staphylococci. "
05/01/1997 - "These findings suggest that quinupristin/dalfopristin may be useful in the treatment of line-associated infections."
09/01/1996 - "The efficacy of quinupristin-dalfopristin in treating resistant infections has also been suggested by smaller studies and case reports. "

07/01/1992 - "Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus."
01/01/2000 - "In-vitro activity of synercid and related drugs against Streptococcus oralis isolated from septicaemia and endocarditis cases."
07/01/1992 - "The activity of RP 59500 against methicillin-resistant Staphylococcus aureus was studied in vitro and in a rabbit model of aortic valve endocarditis. "
05/01/1997 - "It is concluded that quinupristin/dalfopristin has the potential to treat serious infections such as endocarditis caused by Gram-positive cocci."
07/01/2002 - "Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study."

05/01/1997 - "aureus bacteraemia, and quinupristin/dalfopristin may also prove useful in the treatment of pneumococcal infections. "
07/01/1992 - "pneumoniae isolated in France has increased steadily since 1985, RP 59500 might be useful for the treatment of pneumococcal infections and warrants further investigation."
05/01/1997 - "Quinupristin/dalfopristin may prove useful in the treatment of staphylococcal infections in children, invasive systemic pneumococcal infections, and nosocomial and community-acquired Gram-positive infections in patients unable to tolerate beta-lactam antimicrobial agents or glycopeptide antibiotics."

03/01/2000 - "Quinupristin/dalfopristin merits further evaluation for the treatment of nosocomial pneumonia caused by methicillin-resistant S. "
12/01/1999 - "Quinupristin/dalfopristin 7.5 mg/kg 8- or 12-hourly also achieved similar clinical success rates to comparator agents in patients with presumed gram-positive complicated skin and skin structure infections or nosocomial pneumonia (administered in combination with aztreoman) in 3 large multicentre randomised trials. "
09/08/2001 - "NOSOCOMIAL PNEUMONIA DUE TO GRAM-POSITIVE COCCI: In a randomized multicentric trial comparing Synercid with vancomycin, the cure rate (56.3% vs 58.3%) were equivalent in the 2 treatment arms. "
03/01/2000 - "In this study quinupristin/dalfopristin was shown to be equivalent to vancomycin in the treatment of nosocomial pneumonia caused by gram-positive pathogens. "
03/01/2000 - "Two hundred ninety-eight patients with nosocomial pneumonia were enrolled in 74 active centers in five countries: a subgroup of 171 (87 quinupristin/dalfopristin-treated and 84 vancomycin-treated patients) were evaluable for the major efficacy end points. "

05/01/2004 - "The bacteremia resolved in all five patients after therapy with quinupristin/dalfopristin; three patients required central line removal. "
03/01/1999 - "Quinupristin/dalfopristin may have the potential to serve as an alternative agent in the treatment of catheter-related staphylococcal bacteremia. "
01/01/1997 - "Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia."
06/01/2004 - "Persistent VRE bacteremia was successfully treated in this neutropenic patient using the combination of high-dose ampicillin and quinupristin/dalfopristin. "
01/01/2001 - "Outcomes data from clinical trials indicate that quinupristin/dalfopristin has the potential to play an important role in the treatment of bacteremia, complicated skin and skin-structure infections, and nosocomial pneumonia caused by VREF. "